Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes with Concurrent Private…
FROM THE WIRE · MANILATIMES.NET
BOSTON and SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ('Rapport” or the 'Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA roughly 350 million stock and convertible offering may weigh on the stock through dilution.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Rapport commenced separate offerings of $200 million in common stock and $150 million in convertible notes due 2032.
- 02Underwriters may buy an additional $30 million of shares under a 30-day option.
- 03The company is a clinical-stage biotech focused on neurological and psychiatric disorders.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets